Aurinia Pharmaceuticals Inc. Stock Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 227M 310M | Sales 2025 * | 282M 386M | Capitalization | 716M 979M |
---|---|---|---|---|---|
Net income 2024 * | 9M 12.3M | Net income 2025 * | 71M 97.04M | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | 395M 540M | Net cash position 2025 * | 448M 612M | EV / Sales 2025 * | 0.95 x |
P/E ratio 2024 * |
86.6
x | P/E ratio 2025 * |
10.6
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.47% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
1st Jan change | Capi. | |
---|---|---|
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |